health corporation limited

ACN 116 800 269

ASX/Media Release

2 June 2010

Board Changes

Health Corporation Limited (ASX: HEA) confirms the resignation of Board members Mr Graham Dunkley as Chairman and Mr Greg Albert as non-executive directors effective immediately.

The Board wishes to sincerely express their appreciation for the dedication and performance in their respective roles, particularly over the initial period since the company was floated in December 2006.

Mr Jason Davis who joined the board on 14 May 2010 as a non executive director has been appointed Chairman of the board.

The board of the Company is now comprised of:

Ken Lee - Executive Director Jason Davis - Non Executive Chairman Mathew Abrahams - Non Executive Director Tony Ince - Non Executive Director

Change of Registered Office

The Company advises that as of 1 June 2010 the registered office will be located at the following address:

Registered Office: Level 21, Allendale Square 77 St George's Terrace Perth WA 6000 Mailing Address: PO Box Z5184 St Georges Terrace Perth WA 6831

Contact details for the company are detailed below:

Contact Numbers:

Telephone: +61 8 9389 2000 Facsimile: +61 8 9389 2099

All operating businesses of the Company will remain at their current address, and are unaffected by this change to the location of the registered office.

health corporation limited

ACN 116 800 269

ABOUT HEALTH CORPORATION

As advised previously, the Company through its subsidiaries maintains focus on Chemconsult® and Health Information Pharmacy (HIP) franchise businesses, with a particular focus on the Chemconsult® business. The Company has also developed a number of other products through its focus on innovation, and will continue to pursue complementary investment opportunities to maximise future returns to shareholders.

One of the Company's key technologies is Chemconsult®, a proven 10 point system for medication consulting by a pharmacist. This system ensures consistency in advice delivery to the patient, thereby having the potential to reduce medication problems, improve medication compliance and track medication performance in terms of supply and potential adverse drug reactions or other misadventure.

Furthermore, with the help of the new investment syndicate, the Company is actively reviewing other complimentary opportunities to create shareholder value, and is reviewing current activities with a view to reduce exposure to non-core, or loss making activities.

For further information on Health Corporation or Chemconsults® please visit

www.hip.com.au or www.chemconsult.com.au

Jason Davis

For and on behalf of the Board